Skip to main content
. Author manuscript; available in PMC: 2017 Jan 19.
Published in final edited form as: Leukemia. 2015 Dec 21;30(5):1025–1032. doi: 10.1038/leu.2015.346

Figure 3. The sequence of administration for combining FLT3 inhibitors and DNMT inhibitors is crucial.

Figure 3

Molm14 cells were cultured in drug supplemented medium in suspension. The different drugs (the FLT3 inhibitor quizartinib and the two DNMT inhibitors) were given in either sequentially or simultaneously: white bars denote sequential treatment with Quiz first followed by DEC/AZA, black bars represent sequential treatment with DEC/AZA first followed by Quiz, and gray bars denote simultaneous administration of both types of drugs. Following pretreatment, cells were incubated for an additional 48 hours before being harvested for flow cytometry analysis with Annexin V/propidium iodide staining. The mean ± SEM is based on replicate experiments (n= 3). Significant changes in the percentage of growth inhibition are indicated (*p<.05), (**p<.01), (***p<.001).